MOTS-c: A Signal Made Inside the Mitochondria

The short version

MOTS-c is unusual among research peptides because of where it comes from: it is encoded not by a gene in the cell's main nucleus, but by a short stretch of DNA inside the mitochondria — the structures inside almost every cell that turn food into usable energy. The peptide is 16 amino acids long and is highly conserved across mammals, meaning evolution has kept its sequence nearly unchanged for a very long time, a sign that it does something important.

In mice, MOTS-c activates a cellular energy sensor called AMPK, improves how muscle handles blood sugar, and prevented diet-induced obesity and insulin resistance when given to animals on a high-fat diet ^[16]. It has also been shown to boost physical performance in mice across young, middle, and old age ^[14]. What MOTS-c has not yet accumulated is a completed human clinical efficacy trial: the strongest human evidence so far is observational, linking naturally circulating MOTS-c levels to health outcomes rather than testing whether giving more of it helps ^[12]. It is not FDA-approved and is sold, where it is sold, strictly as a research chemical.

What it is

MOTS-c is a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR. What sets it apart structurally is its origin: it is encoded by a small open reading frame tucked inside the gene for the mitochondrial 12S ribosomal RNA (MT-RNR1) — meaning the instructions for building it live in mitochondrial DNA, not in the chromosomes in the cell nucleus where almost all other human genes reside.

That mitochondrial origin puts MOTS-c in a small and only recently discovered category, the mitochondrial-derived peptides, or MDPs — short proteins hiding in plain sight inside DNA long assumed to code only for the machinery of energy production itself. Its sequence is highly conserved across mammalian species, a pattern that in evolutionary biology usually signals a peptide is doing something functionally important rather than being an inert byproduct.

How it works

MOTS-c's best-characterized action is an indirect one: it inhibits an early step in a metabolic pathway called the folate cycle, which is also involved in building the molecular building blocks of DNA. Blocking that step raises the level of a molecule called AICAR inside the cell, and AICAR in turn activates AMPK — a master energy-sensing enzyme that cells rely on to respond to low energy or metabolic stress. Once AMPK is switched on, downstream effects follow in skeletal muscle in particular: improved glucose uptake and better insulin sensitivity ^[16].

Under metabolic stress, MOTS-c does something unusual for a peptide made inside the mitochondrion: it moves out of the mitochondrion entirely and travels to the cell nucleus, where it helps regulate which genes get switched on, including a set of antioxidant-defense genes controlled by a protein called NRF2 — the first time this kind of nucleus-directed signaling had been shown for a mitochondria-encoded peptide ^[15]. A 2024 study went further and identified a direct binding partner, an enzyme called casein kinase 2 (CK2), showing that MOTS-c activates CK2 in muscle while suppressing it in fat tissue — a tissue-specific switch that appears to underlie its effects on both muscle glucose uptake and the prevention of muscle wasting ^[11].

What the research shows

A direct molecular target identified (2024). MOTS-c directly binds and activates casein kinase 2 (CK2) in cell-free laboratory systems — the first time a specific molecular target of this kind was identified for the peptide. In mice, tissue-specific CK2 modulation (activated in muscle, suppressed in fat) prevented skeletal muscle wasting and enhanced glucose uptake in muscle across young, aged, high-fat-diet, and immobilized mouse models ^[11].

Human observational data (2024). In a study following 94 people on chronic hemodialysis for a median of about 26 months, circulating MOTS-c levels were independently associated with a combined risk of death and cardiovascular events, and adding MOTS-c to existing risk models modestly improved how well those models predicted outcomes. This is among the strongest human data available for MOTS-c — but it is an observational association between naturally occurring levels and outcomes, not a trial testing whether adding MOTS-c changes anything ^[12].

A 2023 review consolidating the field. A comprehensive review synthesizes MOTS-c's biology — its unusual mitochondrial DNA origin, its AMPK/folate-cycle mechanism, its nuclear translocation, the fact that exercise induces it naturally, and its proposed roles in metabolism, stress adaptation, and aging — and functions as the modern reference point for the field ^[13].

Exercise-inducibility and physical performance (2021). Exercise increases the body's own MOTS-c production in muscle and blood. When researchers gave mice exogenous MOTS-c, it significantly improved treadmill running capacity, grip strength, and gait in aged mice specifically, positioning MOTS-c as what researchers describe as an exercise-mimetic regulator of healthy aging ^[14].

Nuclear translocation under stress (2018). Under metabolic stress, MOTS-c moves from the mitochondrion to the cell nucleus and helps regulate nuclear gene expression through the AMPK pathway, including a set of antioxidant genes controlled by NRF2 — the first demonstration of this kind of retrograde signaling by a mitochondria-encoded peptide ^[15].

The founding discovery (2015). The paper that first identified MOTS-c described a 16-amino-acid peptide, encoded within mitochondrial DNA, that inhibits the folate cycle and activates AMPK; treated mice were protected from age-related and diet-induced insulin resistance and from diet-induced obesity, with skeletal muscle identified as the primary target tissue ^[16].

A diabetic rat heart model (2025). In rats with a model of type 2 diabetes, MOTS-c treatment increased mitochondrial energy-production capacity in heart tissue and was associated with lower fasting blood sugar and reduced thickening of the heart's left ventricle wall ^[17].

Reported effects, cautions & safety

On community-reported experience. Unlike the other two peptides on this desk, MOTS-c does not yet have a substantial, consistent body of self-reported community experience to draw on the way semaglutide and AOD-9604 do — its research-community use is newer and less widespread, and this desk is not going to invent an anecdotal picture that the sources do not support. What follows instead is the caution picture drawn directly from the published literature and the compound's regulatory status.

Cited cautions from the research literature. Every claim about MOTS-c improving metabolism, physical performance, or aging in a living organism comes from cell or animal studies — predominantly mice and rats. The human data that exist are observational associations between naturally circulating MOTS-c and health outcomes, not interventional trials of giving people MOTS-c ^[12]. There is no published, measured human pharmacokinetic profile — no established half-life, bioavailability, or dose-response relationship — so the doses used in rodent studies cannot be translated into a human equivalent ^[16]. MOTS-c is not approved by the FDA for any use and is sold only as a research chemical; product purity and identity are not regulated the way pharmaceuticals are. It is also treated as a prohibited substance in elite sport by anti-doping authorities, who classify mitochondrial-derived and metabolic-modulator peptides among agents banned at all times, with sanctions for athletes who use it.

Where it fits in metabolic signaling

MOTS-c leads this desk not on the strength of its human evidence — it has the thinnest human data of the three — but because it represents a mechanistically distinct layer: a signal generated from inside the mitochondrion rather than delivered to a surface receptor, the way semaglutide works, or extracted from a larger circulating hormone, the way AOD-9604 was designed to work. Its mouse data are genuinely striking, and its discovery reframed how researchers think about what mitochondrial DNA does. Whether that translates into a compound worth human study the way semaglutide already has remains an open, unanswered question. See the comparison page for how all three compare directly.